Do Traders Think Advaxis, Inc. (ADXS) Can Turn Around Thursday?

Thursday, March 03, 2022 10:20 AM | InvestorsObserver Analysts

Mentioned in this article

Do Traders Think Advaxis, Inc. (ADXS) Can Turn Around Thursday?

The market has been high on Advaxis, Inc. (ADXS) stock recently. ADXS gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Advaxis, Inc. has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ADXS!

See Full ADXS Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With ADXS Stock Today?

Advaxis, Inc. (ADXS) stock is flat -1.57% while the S&P 500 has risen 0.11% as of 10:02 AM on Thursday, Mar 3. ADXS is flat $0.00 from the previous closing price of $0.11 on volume of 89,038 shares. Over the past year the S&P 500 has risen 13.46% while ADXS has fallen -86.75%. ADXS lost -$0.14 per share in the over the last 12 months. To screen for more stocks like Advaxis, Inc. click here.

More About Advaxis, Inc.

Advaxis Inc is a clinical stage biotechnology company operating in the United States. It focuses on the discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology which utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate Specific Antigen (PSA) associated with prostate cancer. Click Here to get the full Stock Report for Advaxis, Inc. stock.